Core Viewpoint - Reed's, Inc. has successfully closed a PIPE financing transaction, raising $5.0 million through the sale of 5,000,000 shares at $1.00 per share, aimed at enhancing working capital and supporting growth initiatives [1][2]. Group 1: Financing Details - The PIPE financing closed on September 15, 2025, generating gross proceeds of $5.0 million [1]. - The company sold 5,000,000 shares of common stock at a price of $1.00 per share [1]. Group 2: Strategic Intent - The proceeds from the financing will be used for working capital and general corporate purposes, allowing the company to invest in personnel, marketing, and product innovation [2]. - The CEO emphasized that the enhanced working capital position will provide greater flexibility to strengthen brand presence and expand market share [2]. Group 3: Leadership Changes - Michael Tu has been appointed to the Board of Directors as a corporate governance advisor and securities litigation expert, effective September 15, 2025, replacing Lee Edwards [2][3]. - Mr. Tu brings nearly three decades of experience in corporate governance and securities law, having previously worked as a partner at Orrick and Cooley [3]. Group 4: Company Overview - Reed's, Inc. is a leader in handcrafted, natural ginger beverages, with a portfolio that includes ginger beers, ginger ales, and a new functional soda line [5][6]. - The company was established in 1989 and its beverages are sold in over 32,000 stores nationwide [5].

🚨UPDATE: JAPAN REGULATOR PROPOSES CRYPTO RULE CHANGES TO ALIGN WITH SECURITIES LAW ~ COINTELEGRAPH ...

Core Viewpoint - The complaint against Biohaven alleges violations of federal securities laws due to misleading statements regarding the regulatory prospects of its drug troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder, which could significantly impact the company's business and financial condition [2]. Group 1 - Biohaven's stock price fell by $3.84 per share, or 19.53%, closing at $15.82 per share following the announcement of an extended PDUFA date for the troriluzole NDA, indicating market reaction to regulatory uncertainties [3]. - The FDA extended the PDUFA date for the troriluzole NDA by three months to allow for a full review of recent submissions, and an advisory committee meeting is planned but not yet scheduled [3]. Group 2 - The lead plaintiff in the class action is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [4]. - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4]. Group 3 - Faruqi & Faruqi, LLP is encouraging individuals with information regarding Biohaven's conduct to come forward, including whistleblowers and former employees [5].